Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

This study has been completed.
Sponsor:
Information provided by:
Allergan
ClinicalTrials.gov Identifier:
NCT00249782
First received: November 3, 2005
Last updated: May 27, 2011
Last verified: May 2011

November 3, 2005
May 27, 2011
November 2005
May 2006   (final data collection date for primary outcome measure)
  • Efficacy: Percent change and change from baseline in inflammatory lesion counts;
  • "Success" rate, defined as proportion of subjects with a score of 0 or 1 and at least a 2 point improvement from baseline on the IGA scale;
  • Erythema & telangiectasia scores;
  • Lesion counts over time
Same as current
Complete list of historical versions of study NCT00249782 on ClinicalTrials.gov Archive Site
  • Safety: Adverse events and concomitant medications; Local symptom scores; Hematology and chemistry laboratory parameters; Vital signs
  • Other: Plasma dapsone concentrations
Same as current
Not Provided
Not Provided
 
A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.
A Phase II, Randomized, Partial-Blind, Parallel-Group, Active- and Vehicle-Controlled, Multicenter Study of the Safety and Efficacy of ACZONE™ (Dapsone) Gel, 5% in Subjects With Papulopustular Rosacea

The purpose of this study is to evaluate the safety and effectiveness of ACZONE™ gel compared to placebo (inactive substance), MetroGel® and a combination of ACZONE™ gel and MetroGel® for the treatment of rosacea.

ACZONE™ gel, 5% is a topical (applied to the skin) medication that is approved by the United States Food and Drug Administration (FDA) for the treatment of acne vulgaris in people 12 years and older. The use of ACZONE™ for the treatment of rosacea is investigational. An investigational use is one that is not approved by the FDA.

Subjects will apply the study treatment for 12 weeks. Efficacy assessments will be performed at baseline and Weeks 2, 4, 8, and 12. Laboratory assessments will be conducted at baseline and Week, 2, 4 and 12.

Study Objective:

•To evaluate the safety and preliminary efficacy of ACZONE in subjects with papulopustular rosacea

Study Population: Approximately 400 male and female subjects will be enrolled at 27 study centers in the United States.

Study Treatment: Subjects will be randomized to 1 of 5 treatment regimens. Subjects will receive study medication for 12 weeks. Study participation is 13 weeks (5 clinic visits and 1 telephone follow-up).

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Rosacea
  • Drug: Vehicle control, 2x/day
  • Drug: ACZONE (dapsone) Gel, 5%, 2x/day
  • Drug: ACZONE (dapsone) Gel, 5%, 1x/day
  • Drug: MetroGel® (metronidazole gel), 1.0% 1x/day
  • Drug: ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
May 2006
May 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

To be eligible for the study, subjects must fulfill all of the following criteria:

  1. Men or women ≥18 years of age.
  2. A diagnosis of papulopustular rosacea, with ≥10 inflammatory lesions (papules and/or pustules) above the mandibular line at baseline.
  3. An Investigator Global Assessment (IGA) score ≥2
  4. In good physical and mental health.
  5. Signature of an approved informed consent form for the study and HIPAA authorization (if applicable).
  6. Willingness to comply with the protocol.

Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from the study:

  1. A skin examination reveals the presence of another skin disease and/or condition (excessive facial hair, excessive scarring, sunburn, or other disfigurement) located on the face that would confound the evaluation of the rosacea condition.
  2. Current or past ocular rosacea, such as conjunctivitis, iritis, and keratitis, of sufficient severity to require topical or systemic antibiotics.
  3. Treatment with topical antibiotics, topical steroids and other topical rosacea treatments on the face within 14 days of Baseline and throughout the study.
  4. Treatment with systemic steroids within 30 days of Baseline and throughout the study.
  5. Treatment with any systemic antibiotics within 30 days of Baseline and throughout the study.
  6. Treatment with any systemic medication or therapy known to affect inflammatory responses within the 30 days prior to Baseline or throughout the study.
  7. Treatment with topical retinoids within 30 days or systemic retinoids within 180 days of Baseline and throughout the study.
  8. Treatment with physical modalities that could benefit rosacea are prohibited within 30 days of Baseline and throughout the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00249782
ACZ ROS 01
Not Provided
Not Provided
Allergan
Not Provided
Study Director: Steven Garrett, MS, DDS QLT USA, Inc.
Allergan
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP